Biotech Intuition

SOZO Intution

Biotech Intuition helps you understand the biotechnology developments that matter—without the noise. Each concise episode highlights the day’s most consequential clinical results, regulatory decisions, scientific advances, partnerships, financings, and industry developments. We explain what happened, why it matters, the important uncertainties, and what to watch next. Produced by SOZO Intuition, the biotechnology intelligence platform connecting companies, therapeutics, technologies, diseases, research, and industry news. Episodes are AI-narrated and reviewed against original sources. Sources and further reading are included in the show notes.

  1. 1d ago

    Daily - Nov 19,2026

    Daily - Nov 19,2026 — Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com Chapters00:00 Biotech Intuition Brief00:39 FDA Approves Livsayis for Generalized Myasthenia Gravis01:15 Livsayis Approval Triggers $25M Milestone to Alnylam01:40 FDA Approves Sanofi's Infilbray for Type 3 Gaucher Disease02:06 Infilbray Crosses Blood-Brain Barrier in Type 3 Gaucher02:33 AbbVie, DISCO Partner on Bispecific Solid Tumor Therapies03:01 DISCO Eligible for Up to $2.5B in AbbVie Collaboration03:29 Merck, Isomorphic Labs Form Multi-Target AI Drug Pact04:11 FDA Expands Breyanzi Label to CNS Lymphoma Patients04:39 Scancell's iSCIB1-plus Receives FDA RMAT Designation05:14 Adcendo Presents Phase 1 Data for ADCE-D01 in Sarcoma05:52 Looking ahead06:56 SOZO Intuition SummaryWelcome to today's biotech briefing. Today we are tracking three major developments across clinical and regulatory pipelines, led by Food and Drug Administration approval for Regeneron and Alnylam Pharmaceuticals' complement-directed therapy Livsayis for generalized myasthenia gravis, a landmark FDA clearance for Sanofi's Infilbray to treat neurological symptoms of Type 3 Gaucher disease, and an oncology research collaboration between AbbVie and DISCO Pharmaceuticals committing up to two and a half billion dollars toward bispecific antibody programs for solid tumors. Sources are in the show notes. Sources by chapter Biotech Intuition Brief FDA Approves Livsayis for Generalized Myasthenia GravisAlnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ cemdisiran in Generalized Myasthenia Gravis 2026-11-19 Livsayis Approval Triggers $25M Milestone to Alnylam FDA Approves Sanofi's Infilbray for Type 3 Gaucher DiseaseSanofi Secures FDA Approval for Infilbray venglustat in Type 3 Gaucher Disease 2026-11-19 Infilbray Crosses Blood-Brain Barrier in Type 3 Gaucher AbbVie, DISCO Partner on Bispecific Solid Tumor TherapiesAbbVie Enters Up to $2.5B Bispecific Oncology Collaboration with DISCO Pharmaceuticals 2026-11-19 DISCO Eligible for Up to $2.5B in AbbVie Collaboration Merck, Isomorphic Labs Form Multi-Target AI Drug PactMerck and Isomorphic Labs Enter Strategic Research Collaboration 2026-11-19 FDA Expands Breyanzi Label to CNS Lymphoma PatientsFDA Removes CNS Lymphoma Limitation from Breyanzi liso-cel Prescribing Information 2026-11-19 Scancell's iSCIB1-plus Receives FDA RMAT Designation Adcendo Presents Phase 1 Data for ADCE-D01 in SarcomaAdcendo Announces Phase 1 Clinical Data for ADCE-D01 in Advanced Soft Tissue Sarcoma 2026-11-19 Looking aheadVelzatinib Granted Orphan Drug Designation ODD in Japan for GIST 2026-11-19Opus Genetics Doses First Participant in Phase 1/2 Clinical Trial of OPGx-RDH12 2026-11-19 SOZO Intuition

  2. 1d ago

    Daily - Nov 18, 2026

    Daily - Nov 18, 2026 — Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com Chapters00:00 SOZO Biotech Daily Brief01:12 Isomorphic Labs Closes $5B Series C Financing01:43 Capital to Expand IsoDDE Platform and Pipeline02:01 FDA Approves Roche's Wilserdly in Breast Cancer02:31 Targeted Endocrine Option and Near-Term Decision02:49 SELLAS Reports Positive Phase 3 REGAL Data in AML03:23 SELLAS Prepares Accelerated Approval BLA Submission03:42 Lilly and Stipple Bio Form Up to $5.9B Alliance04:15 Summit Initiates Phase III Trial in Stage III NSCLC04:53 Biocon Secures European Biosimilar Approval05:23 Immunome and INOVIO File for EMA Approval of VOCERYQ06:00 Looking Ahead06:33 SOZO Intuition Platform SummaryWelcome to today’s SOZO biotech daily brief. We lead with an unprecedented private financing, as Alphabet subsidiary Isomorphic Labs raises five billion dollars to scale its artificial intelligence drug design engine and advance both internal and partnered programs into human clinical trials. On the regulatory front, Roche has captured United States approval for Wilserdly, securing the first green light for an oral selective estrogen receptor degrader in combination with everolimus for advanced ESR1-mutated breast cancer. In clinical developments, SELLAS Life Sciences announced that its WT1-targeting cancer vaccine galinpepimut-S achieved a statistically significant and clinically meaningful overall survival improvement in acute myeloid leukemia patients in second complete remission. Looking ahead, watch for an additional FDA decision for Roche in early-stage breast cancer later this month, an accelerated regulatory submission from SELLAS planned for the first half of 2027, and interim Phase III psoriasis data from Can-Fite BioPharma in the first quarter of 2027. Sources are in the show notes. Sources by chapter SOZO Biotech Daily Brief Isomorphic Labs Closes $5B Series C FinancingFinancing, M&A, and Strategic Deals Capital to Expand IsoDDE Platform and Pipeline FDA Approves Roche's Wilserdly in Breast CancerRegulatory and Product Advancements Targeted Endocrine Option and Near-Term Decision SELLAS Reports Positive Phase 3 REGAL Data in AMLRegulatory and Product AdvancementsClinical Trial Results SELLAS Prepares Accelerated Approval BLA Submission Lilly and Stipple Bio Form Up to $5.9B AllianceFinancing, M&A, and Strategic Deals Summit Initiates Phase III Trial in Stage III NSCLCRegulatory and Product AdvancementsClinical Trial Results Biocon Secures European Biosimilar Approval Immunome and INOVIO File for EMA Approval of VOCERYQ Looking AheadIsomorphic Labs SOZO Intuition Platform

  3. 4d ago

    Daily - Nov 2, 2026

    Daily - Nov 2, 2-26 — Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com Chapters00:00 Today's Lead Biotech Stories00:27 FDA Grants Accelerated Approval to VOCERYQ00:53 INOVIO Confirmatory Trial and Launch Timeline01:10 Teva Halts Phase 2 TOPAS-MSA Trial for Futility01:37 Karyopharm Files Chapter 11 and Plans Ayrmid Merger02:00 Alligator Out-Licenses Mitazalimab to Biossil02:28 SEC Declares Chemomab-Scipher Merger S-4 Effective02:49 Samsung Biologics Advances PolyPeptide Group Buyout03:06 Enlivex Reports 12-Month Allocetra Topline Data03:28 Looking ahead04:01 SOZO Intuition SummaryToday on the SOZO biotech daily, we track three major developments across the sector: INOVIO secures accelerated FDA approval for VOCERYQ in recurrent respiratory papillomatosis, Teva discontinues its Phase 2 study of emrusolmin in multiple system atrophy following an interim futility review, and Karyopharm Therapeutics enters Chapter 11 restructuring with plans to merge with Ayrmid. Sources are in the show notes. Sources by chapter Today's Lead Biotech Stories FDA Grants Accelerated Approval to VOCERYQINOVIO receives FDA accelerated approval for VOCERYQ in recurrent respiratory papillomatosis 2026-11-02 INOVIO Confirmatory Trial and Launch Timeline Teva Halts Phase 2 TOPAS-MSA Trial for FutilityTeva to discontinue Phase 2 TOPAS-MSA study of emrusolmin after interim futility analysis 2026-11-02 Karyopharm Files Chapter 11 and Plans Ayrmid MergerKaryopharm announces planned merger with Ayrmid under Chapter 11 restructuring 2026-11-02 Alligator Out-Licenses Mitazalimab to BiossilAlligator Bioscience to sell mitazalimab rights to Biossil for $0.75 million upfront 2026-10-31Fresenius Kabi and WuXi Biologics sign exclusive biosimilars development agreement 2026-11-02 SEC Declares Chemomab-Scipher Merger S-4 EffectiveChemomab and Scipher Medicine S-4 registration statement declared effective 2026-11-02 Samsung Biologics Advances PolyPeptide Group BuyoutSamsung Biologics reports 97.66% provisional participation in PolyPeptide tender offer 2026-11-02 Enlivex Reports 12-Month Allocetra Topline DataEnlivex reports 12-month Phase I/IIa Allocetra results in knee osteoarthritis 2026-11-02 Looking aheadMirum Pharmaceuticals presents Phase 3 brelovitug and Phase 2b volixibat data at AASLD 2026 2026-11-02 SOZO Intuition

  4. 4d ago

    Daily - Oct 30, 2026

    Daily - Oct 30, 2026 — Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com Chapters00:00 Today's Highlights00:55 Pelthos and Castle Creek to Merge Operations01:40 Merger Structure and D-Fi Development Plans02:15 China Grants Priority Review for Hengrui's ADC03:02 SHR-A1811 Met Primary Endpoint in Phase 3 Trial03:47 Moleculin Completes Dosing in Part A of MIRACLE04:24 MIRACLE Data Readout Slated for 202704:48 CLINUVEL Files NEURACTHEL Instant in Europe05:15 Celularity Partners with Vesalius on Peptides06:04 Repligen Announces $1B Convertible Notes Offering06:40 Looking Ahead SummaryWelcome to the SOZO biotech daily. Today we lead with a definitive merger agreement between Pelthos Therapeutics and Castle Creek Biosciences to establish a serious-skin-disease company centered on late-stage cell therapy, China’s priority review designation for Jiangsu Hengrui Medicine’s antibody-drug conjugate SHR-A1811 in advanced breast cancer, and Moleculin Biotech completing patient dosing in the initial stage of its registrational acute myeloid leukemia trial. Looking ahead, key developments to track include the initiation of the continued late-stage study for Castle Creek's lead gene-modified cell therapy, China's forthcoming regulatory decision on Hengrui's priority breast cancer submission, and Moleculin's upcoming data readout in 2027 to establish dose selection for the next phase of clinical evaluation. Sources are in the show notes. Sources by chapter Today's Highlights Pelthos and Castle Creek to Merge OperationsPelthos Therapeutics and Castle Creek Biosciences Agree to Merge Around a Phase 3 Dystrophic Epidermolysis Bullosa Program 2026-10-30 Merger Structure and D-Fi Development Plans China Grants Priority Review for Hengrui's ADCChina's NMPA Grants Priority Review to Hengrui's SHR-A1811 for HER2-Positive Breast Cancer 2026-10-29 SHR-A1811 Met Primary Endpoint in Phase 3 Trial Moleculin Completes Dosing in Part A of MIRACLEMoleculin Completes Part A Dosing in Pivotal MIRACLE Trial of Annamycin in Relapsed or Refractory AML 2026-10-29 MIRACLE Data Readout Slated for 2027 CLINUVEL Files NEURACTHEL Instant in EuropeCLINUVEL Files NEURACTHEL Instant Dossier with European Regulators 2026-10-29 Celularity Partners with Vesalius on PeptidesCelularity and Vesalius Longevity Labs Sign Exclusive U.S. Manufacturing Collaboration for Peptual Peptide APIs 2026-10-29 Repligen Announces $1B Convertible Notes OfferingRepligen Announces $1 Billion Private Convertible Senior Notes Transaction 2026-10-29 Looking Ahead

  5. Oct 22

    Biotech Daily Top Stories - October 22, 2026

    Daily - Oct 22, 2026 - Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com SUMMARYWelcome to the SOZO biotech daily brief. Today, our lead stories cover an FDA accelerated approval for AstraZeneca in primary immunoglobulin A nephropathy, mid-stage clinical trial results from Lumen Bioscience in Clostridioides difficile, and a multi-target miniprotein discovery alliance between Astellas Pharma and AI Proteins. We also follow pipeline progress from Newron Pharmaceuticals and Thiogenesis Therapeutics, alongside new venture backing for Reju Therapeutics. Sources are in the show notes. CHAPTERS AND SOURCES 00:00 - SOZO Biotech Daily Brief 00:34 - AstraZeneca's Ultomiris Wins FDA Accelerated ApprovalUltomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A…:https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html 01:38 - Lumen Reports Phase 2 RePreve Results for LMN-201Lumen's LMN-201 shows positive RePreve Phase 2 results in C. difficile 2026-10-22:https://www.lumen.bio/2026/10/22/lumen-s-lmn-201-shows-positive-re-preve-results-in-c-difficile 02:32 - Astellas and AI Proteins Form Miniprotein Discovery PactAstellas Pharma and AI Proteins enter miniprotein discovery collaboration valued at over $400 million 2026-10-21:https://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million 03:18 - Newron Completes Phase 3 ENIGMA-TRS 1 EnrollmentNewron completes enrollment of pivotal Phase 3 ENIGMA-TRS 1 study of evenamide 2026-10-22:https://www.newron.com/news-and-media/regulatory-news/newron-completes-enrollment-pivotal-phase-3-enigma-trs-1-study 03:54 - FDA Clears TTI-0102 IND in Nephropathic CystinosisThiogenesis announces FDA clearance of IND for TTI-0102 in nephropathic cystinosis 2026-10-22:https://finance.yahoo.com/healthcare/articles/thiogenesis-announces-fda-clearance-ind-090000510.html 04:29 - Nanjing Reju Therapeutics Closes Oversubscribed Series AReju Therapeutics completes oversubscribed Series A financing 2026-10-21:https://www.vcbeathealth.com/article/63807 04:57 - Looking ahead 05:32 - SOZO Intuition

    Biotech Daily Top Stories - October 22, 2026
  6. Oct 21

    Biotech Daily Top Stories - October 21, 2026

    Daily - Oct 21, 2026 - Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com CHAPTERS00:00 SOZO Biotech Daily Brief00:35 Fenebrutinib Cuts Relapse Rate in Multiple Sclerosis01:11 Fenebrutinib Slows Chronic Brain Lesion Progression01:46 Genentech Highlights Pediatric Ocrevus and Enspryng02:23 Miv-cel Shows 1-Year Mobility Gains in Stiff Person03:00 Miv-cel Enables Immunotherapy Freedom at One Year03:38 Oral Olorofim Meets Non-Inferiority in Aspergillosis04:12 Olorofim Reduces Renal Injury; Resubmission Planned04:48 FDA Approves ORLADEYO Oral Pellets for HAE05:30 LMN-201 Biologic Cocktail Succeeds in Phase 2 C. diff06:13 BIOX-101 Reduces Edema Growth in Brain Hemorrhage06:56 Servier Partners with Okomera on Tumor Miniaturization07:37 Looking ahead08:24 SOZO Intuition SUMMARY SOURCES BY CHAPTER SOZO BIOTECH DAILY BRIEF FENEBRUTINIB CUTS RELAPSE RATE IN MULTIPLE SCLEROSISGenentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21:https://www.gene.com/media/press-releases/15139/2026-10-21/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026 FENEBRUTINIB SLOWS CHRONIC BRAIN LESION PROGRESSION GENENTECH HIGHLIGHTS PEDIATRIC OCREVUS AND ENSPRYNG MIV-CEL SHOWS 1-YEAR MOBILITY GAINS IN STIFF PERSONKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto…:https://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.htmlQuell Therapeutics Advances QEL-005 to Second Dose Cohort in CHILL Phase 1/2 Trial in Rheumatoid Arthritis and Systemic Sclerosis 2026-10-21:https://www.biospace.com/press-releases/promising-early-safety-data-as-quell-therapeutics-advances-qel-005-a-novel-engineered-ntreg-therapy-to-second-dose-cohort-in-chill-phase-1-2-trial-in-difficult-to-treat-rheumatoid-arthritis-and-systemic-sclerosisArctic Therapeutics Closes Oversubscribed US$21.5 Million Financing 2026-10-21:https://www.prnewswire.com/news-releases/arctic-therapeutics-closes-oversubscribed-us21-5-million-financing-302915211.html MIV-CEL ENABLES IMMUNOTHERAPY FREEDOM AT ONE YEAR ORAL OLOROFIM MEETS NON-INFERIORITY IN ASPERGILLOSISShionogi and F2G Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome Followed by Standard of Care in Invasive…:https://www.shionogi.com/global/en/news/2026/10/e20261021_3.html OLOROFIM REDUCES RENAL INJURY; RESUBMISSION PLANNED FDA APPROVES ORLADEYO ORAL PELLETS FOR HAEBioCryst Announces U.S. FDA Approval of ORLADEYO 150 mg Oral Pellets for Adults and Adolescents with Hereditary Angioedema 2026-10-21:https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html LMN-201 BIOLOGIC COCKTAIL SUCCEEDS IN PHASE 2 C. DIFFLumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial of LMN-201 for C. difficile Infection 2026-10-21:https://www.prnewswire.com/news-releases/lumen-bio-reports-positive-phase-2-results-from-the-repreve-clinical-trial-lmn-201-for-c-difficile-infection-302915046.html BIOX-101 REDUCES EDEMA GROWTH IN BRAIN HEMORRHAGEBioxodes BIOX-101 Phase 2a Data Show Statistically Significant Reduction in Perihematomal Edema Growth in Intracerebral Hemorrhage 2026-10-21:https://www.bioxodes.com/newsroom/press-releases/bioxodes-biox-101-phase-2a-data-show-statistically-significant-reduction-in-perihematomal-edema-growth-in-intracerebral-hemorrhage SERVIER PARTNERS WITH OKOMERA ON TUMOR MINIATURIZATIONOkomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research 2026-10-21:https://www.okomera.com/_files/ugd/631ec0_f041bdf1df614649962c581bf1a5e735.pdf LOOKING AHEADAkeso Announces Summit Therapeutics and ECOG-ACRIN Enter a Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer…:https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.htmlMuna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator MNA-001 in Alzheimer Disease 2026-10-21:https://www.prnewswire.com/news-releases/muna-therapeutics-announces-positive-phase-1-results-supporting-potential-of-oral-small-molecule-trem2-modulator-mna-001-in-alzheimers-disease-302914619.htmlAdditional references omitted to fit YouTube's 5,000-character limit.

  7. Oct 20

    Biotech Daily Top Stories - Oct 20, 2026

    Daily - Oct 20, 2026 v2 - Show Notes Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:https://sozointuition.com CHAPTERS00:00 Biotech Daily Briefing00:43 RAP-219 Meets Primary Endpoint in Acute Bipolar Mania01:32 RAP-219 Validates Selective Mechanism in Acute Mania02:12 Casdatifan Shows Efficacy in Renal Cell Carcinoma03:02 Casdatifan Delivers 35-Month Median Overall Survival03:46 Duvakitug Sustains Efficacy in Inflammatory Bowel Disease04:43 FDA Approves Process 2.0 for Alvotech's SIMLANDI05:27 Ambrose Acquires AM-Pharma for up to 161 Million Euros06:16 Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial07:06 Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric07:50 Looking ahead08:31 SOZO Intuition SUMMARYWelcome to today's biotech daily briefing. Today, we lead with positive mid-stage clinical proof-of-concept data from Rapport Therapeutics in acute bipolar mania, expansive platform trial results from Arcus Biosciences evaluating casdatifan across multiple lines of clear cell renal cell carcinoma, and long-term extension data from Teva and Sanofi demonstrating sustained efficacy for duvakitug in inflammatory bowel disease. We also follow regulatory and clinical advancements spanning biomanufacturing, rare disease acquisitions, critical care respiratory medicine, and gastrointestinal oncology. Sources are in the show notes. CHAPTERS AND SOURCES 00:00 - Biotech Daily Briefing 00:43 - RAP-219 Meets Primary Endpoint in Acute Bipolar ManiaRapport Therapeutics Reports Positive Phase 2 Results for RAP-219 in Bipolar Mania 2026-10-20:https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htmPolarityBio Phase 3 COVER DFUS II Meets Primary Endpoint in Diabetic Foot Ulcers 2026-10-20:https://www.biospace.com/press-releases/polaritybio-highlights-highest-scoring-abstract-award-and-presentation-of-phase-3-cover-dfus-ii-trial-results-at-sawc-fall-2026 01:32 - RAP-219 Validates Selective Mechanism in Acute Mania 02:12 - Casdatifan Shows Efficacy in Renal Cell CarcinomaArcus Biosciences Presents ARC-20 Data for Casdatifan Across ccRCC Lines 2026-10-20:https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm 03:02 - Casdatifan Delivers 35-Month Median Overall Survival 03:46 - Duvakitug Sustains Efficacy in Inflammatory Bowel DiseaseTeva and Sanofi Report 44-Week Phase 2b Data for Duvakitug in IBD 2026-10-20:https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspxOdyssey Therapeutics Reports Phase 2a OD-001 Data in Ulcerative Colitis 2026-10-20:https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-ex99_1.htm 04:43 - FDA Approves Process 2.0 for Alvotech's SIMLANDIAlvotech Receives FDA Approval for New SIMLANDI Manufacturing Process 2026-10-20:https://www.biospace.com/press-releases/alvotech-receives-fda-approval-for-new-simlandi-manufacturing-process-that-more-than-doubles-output-per-batch 05:27 - Ambrose Acquires AM-Pharma for up to 161 Million EurosAmbrose Healthcare Acquires AM-Pharma for Up to €161 Million 2026-10-20:https://www.biospace.com/press-releases/ambrose-healthcare-acquires-am-pharma-for-up-to-161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base 06:16 - Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage TrialNano24 Reports Positive Phase 2b Results for Inhaled EXO-CD24 in ARDS 2026-10-20:https://www.businesswire.com/news/home/20261020667516/en/Nano24-Reports-Positive-Phase-2b-Results-for-Inhaled-EXO-CD24-in-Acute-Respiratory-Distress-Syndrome-ARDS-at-the-CHEST-Annual-Meeting-2026 07:06 - Phase 3 RELIGHT Data for Retlirafusp Alfa in GastricHengrui's Retlirafusp Alfa RELIGHT Phase 3 Results Published in JCO 2026-10-20:https://www.hengrui.com/media/detail-1054.html 07:50 - Looking aheadAstraZeneca and Oracle Launch Global AI Collaboration for Clinical Trial Optimisation 2026-10-20:https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-oracle-launch-global-ai-collaboration-advance-clinical-trial-optimisation-support-better-patient-outcomes.htmlAdocia Raises €7 Million and Extends Cash Runway to 2028 2026-10-20:https://www.adocia.com/composants/uploads/2026/10/ADOCIA-PR-FINANCING-OPERATION-OCTOBER-2026.pdf 08:31 - SOZO Intuition

    Biotech Daily Top Stories - Oct 20, 2026

About

Biotech Intuition helps you understand the biotechnology developments that matter—without the noise. Each concise episode highlights the day’s most consequential clinical results, regulatory decisions, scientific advances, partnerships, financings, and industry developments. We explain what happened, why it matters, the important uncertainties, and what to watch next. Produced by SOZO Intuition, the biotechnology intelligence platform connecting companies, therapeutics, technologies, diseases, research, and industry news. Episodes are AI-narrated and reviewed against original sources. Sources and further reading are included in the show notes.